Clinical Trial

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Protocol Amendment History 24 amendments
This ClinicalTrials.gov record has been amended 24 times since 2024-09-27; most recent amendment 2025-12-12.
Status change: Not Yet Recruiting → Recruiting 2024-11-01
Trial Details
NCT Number NCT06619561
Lead Sponsor Deciphera Pharmaceuticals, LLC
Conditions Chronic Graft-Versus-Host Disease (cGVHD)
Enrollment 48 participants
Start Date 2024-11-21
Primary Completion 2029-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-15